119 HR 8630

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

Congress119
ChamberHouse
TypeHR
Number8630
Introduced2026-04-30
Cosponsors1

Latest Action

Referred to the House Committee on Energy and Commerce.

2026-04-30

Read the Bill

Primary sources on Congress.gov:

Cosponsors (showing 1 of 1)

R · Harshbarger, Diana (Tennessee)

Persona Takes on This Bill

Statement-vs-Vote Gap (Pressure Desk)

The War Powers flood and CFPB disapprovals are unified by a gap between public legislative urgency and zero structural path to passage — these are electoral record-building instruments being described as legislative pressure campaigns.

The gap I'm tracking today is between the volume of legislative language and the absence of any cross-aisle commitment. Nine War Powers resolutions in roughly three weeks — that is an extraordinary number of separately introduced instruments. Each introduction generates floor statements, press releases, constituent mailings, and earned media. Gottheimer's 119hconres75 even got a unanimous consent agreement that sounds like a breakthrough. But the UC agreement was structured so that the Republican committee chair holds the trigger. That gap — between the appearance of procedural progress and the reality of Republican gate-keeping — is the core deception in today's legislative record. Someone said 'we secured a path to the floor.' The record says that path has a Republican-controlled lock on it. The FEC data in this input does not include specific independent expenditure figures for named candidates in this cycle, so I cannot cite specific dollar flows anchoring this analysis — that's a gap I'll flag rather than paper over. What I can say is that the pattern of behavior here is consistent with a minority party building an electoral record rather than passing legislation. The sponsors — Gottheimer, Moulton, Jayapal, Huffman, Balint — span the Democratic ideological spectrum from center to progressive. That breadth is itself a signal: this is being built as a coalition document for 2026 campaign use, not a negotiated vehicle with majority-party buy-in. On the CFPB resolutions: Green and Beatty introducing disapprovals with zero cosponsors and no Republican engagement is the definition of a statement vote that will never happen. The CFPB rule withdrawals being targeted were controversial and drew industry lobbying; the silence of the financial services industry on these disapproval resolutions — no public opposition, no counter-mobilization — tells you exactly how threatened they are by these bills. They aren't. The market for these resolutions is the constituent newsletter, not the committee markup.

2026-05-13

Federal Agencies on This Bill

Posts from federal agencies in the last 24 hours that match this bill's identifier or title keywords. Grouped by voice class — executive framing carries the administration's perspective; regulators speak to implementation; oversight bodies aim for neutrality. Read across, not just within, a single voice class.

Executive branch (framing — read with awareness)

Press releases and statements from cabinet departments and the White House. These are the administration's own framing on the bill or its policy area, not neutral analysis.

Labor Department executive Sun, 10 Ma

Trump Administration proposes rule to expand access to fertility benefits with new legal pathway for employers to offer benefits directly to employees

WASHINGTON – The U.S. departments of Labor, Health and Human Services, and Treasury announced a proposed rule that would create a new category of limited excepted benefits to further expand the ability of employers to offer meaningful fertility benefits to their employees. T

Independent oversight (CBO, GAO, Federal Register, Congress.gov)

Non-partisan analysis: CBO cost scoring, GAO investigations, Federal Register rule publications, and Congress.gov legislative tracking. The closest thing to neutral framing on a bill's likely effect.

GAO (oversight) oversight Wed, 06 Ma

High-Tech Medical Equipment: VA Has Opportunities to Improve Its Acquisition of Maintenance Services

What GAO Found The Department of Veterans Affairs (VA) spends hundreds of millions of dollars annually to buy and maintain high-tech medical equipment (HTME)—such as magnetic resonance imaging equipment—to deliver health care to veterans. To maintain this equipment, and help ensu

GAO (oversight) oversight Thu, 07 Ma

U.S. Ports of Entry: Update on CBP Public-Private Partnership Programs

What GAO Found Since GAO's January 2024 report, U.S. Customs and Border Protection (CBP) continued to expand its public-private partnership programs—the Reimbursable Services Program (RSP) and the Donations Acceptance Program (DAP). The RSP ensures partners, such as port authorit

Markets vs Bill

No directly-mapped prediction markets indexed yet for this bill's policy domain.
Cite this page

APA

Apprised.news. (n.d.). 119 HR 8630: To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.. Retrieved 2026-05-13, from https://apprised.news/bill/119hr8630

MLA

"119 HR 8630: To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.." Apprised.news. Web. 2026-05-13. <https://apprised.news/bill/119hr8630>.

Chicago

"119 HR 8630: To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.." Apprised.news. Accessed 2026-05-13. https://apprised.news/bill/119hr8630.

BibTeX

@misc{apprised_119_hr_8630_to_amend_the_public_health_s,
  title = {119 HR 8630: To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.},
  publisher = {Apprised.news},
  url = {https://apprised.news/bill/119hr8630},
  note = {Accessed 2026-05-13}
}